Details of the Drug Combination

General Information of Drug Combination (ID: DC1J0UP)

Drug Combination Name
OSI-027 TAK-733
Indication
Disease Entry Status REF
Glioblastoma Investigative [1]
Component Drugs OSI-027   DMJX3O8 TAK-733   DMC4RNA
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: JHH-136
Zero Interaction Potency (ZIP) Score: 65.82
Bliss Independence Score: 64.27
Loewe Additivity Score: 14.94
LHighest Single Agent (HSA) Score: 18.18

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of OSI-027
Disease Entry ICD 11 Status REF
Renal cell carcinoma 2C90 Phase 2 [2]
OSI-027 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of TAK-733
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
TAK-733 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
MAPK/ERK kinase kinase (MAP3K) TTROQ37 NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406.
3 ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
4 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
5 MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.